Figure 3.

The comparative treatment effect (delta between change in the National Institutes of Health-Chronic Prostatitis Symptom Index score in the treatment group compared with the placebo group) seen in the available randomized, placebo-controlled trials available in the literature. Except for the α-blocker studies and 2 small (fewer than 30 patients in the mepartricin and quercetin trials) single-center studies, none of the usual medications that are employed clinically for the prostatitis syndromes demonstrated a significant treatment effect. PPS, pentosan polysulfate. Data from Nickel JC,¹⁴ Nickel JC,¹⁹ and Dimitrakov JD et al.²⁰